ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD
Executive Summary
Proposed list of topics for review in 2019 by the Institute for Clinical and Economic Review includes a total of 15 drugs but that could change as the year goes on.
You may also be interested in...
J&J Foresees Broad Insurance Coverage For Groundbreaking Spravato Nasal Spray
Datamonitor projects the newly US FDA-approved esketamine product for treatment-resistant depression will reach sales of almost $2bn in the US, Japan and five major European markets.
ICER’s ‘Unsupported Price Increase’ Report Due This Fall
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
J&J Seeks A Priority Review For Depression Drug Esketamine
Janssen filed an NDA for esketamine nasal spray for treatment-resistant depression with FDA, which could grant a six-month priority review.